Ayalew Tefferi, Paola Guglielmelli, Dirk R Larson, Christy Finke, Emnet A Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A Belachew, Terra L Lasho, Rhett P Ketterling, Curtis A Hanson, Alessandro Rambaldi, Guido Finazzi, Juergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M Vannucchi
Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). We examined the effect of these mutations on long-term disease outcome. One thousand five hundred eighty-one patients from the Mayo Clinic (n = 826) and Italy (n = 755) were studied. Fifty-eight percent of Mayo patients were followed until death; median survivals were 19...
October 16, 2014: Blood